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Abstract
Background: The Psychiatric arm of the population-based CoLaus study (PsyCoLaus) is designed
to: 1) establish the prevalence of threshold and subthreshold psychiatric syndromes in the 35 to 66
year-old population of the city of Lausanne (Switzerland); 2) test the validity of postulated
definitions for subthreshold mood and anxiety syndromes; 3) determine the associations between
psychiatric disorders, personality traits and cardiovascular diseases (CVD), 4) identify genetic
variants that can modify the risk for psychiatric disorders and determine whether genetic risk
factors are shared between psychiatric disorders and CVD. This paper presents the method as well
as sociodemographic and somatic characteristics of the sample.
Methods: All 35 to 66 year-old persons previously selected for the population-based CoLaus
survey on risk factors for CVD were asked to participate in a substudy assessing psychiatric
conditions. This investigation included the Diagnostic Interview for Genetic Studies to elicit
diagnostic criteria for threshold disorders according to DSM-IV and algorithmically defined
subthreshold syndromes. Complementary information was collected on potential risk and
protective factors for psychiatric disorders, migraine and on the morbidity of first-degree relatives,
whereas the collection of DNA and plasma samples was already part of the original CoLaus survey.
Results: A total of 3,691 individuals completed the psychiatric evaluation (67% participation). The
gender distribution of the sample did not differ significantly from that of the general population in
the same age range. Although the youngest 5-year band of the cohort was underrepresented and
the oldest 5-year band overrepresented, participants of PsyCoLaus and individuals who refused to
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participate revealed comparable scores on the General Health Questionnaire, a self-rating
instrument completed at the somatic exam.
Conclusion: Despite limitations resulting from the relatively low participation in the context of a
comprehensive and time-consuming investigation, the PsyCoLaus study should significantly
contribute to the current understanding of psychiatric disorders and comorbid somatic conditions
by: 1) establishing the clinical relevance of specific psychiatric syndromes below the DSM-IV
threshold; 2) determining comorbidity between risk factors for CVD and psychiatric disorders; 3)
assessing genetic variants associated with common psychiatric disorders and 4) identifying DNA
markers shared between CVD and psychiatric disorders.
Background
1. Clinical and epidemiological findings on the association 
between psychiatric disorders and cardiovascular diseases
Both cardiovascular disease (CVD) and psychiatric disor-
ders are major public health issues which lead to
increased mortality and disability. Epidemiological stud-
ies based on structured diagnostic interviews have consist-
ently documented high lifetime prevalence of psychiatric
disorders [1-7] with even higher rates in more recent sur-
veys. Several of these studies [8-10] as well as research in
primary care settings [11] have also revealed a substantial
proportion of individuals that have mood or anxiety
symptoms not meeting diagnostic criteria for correspond-
ing disorders. Although, clinical and a small number of
epidemiological studies have supported the clinical signif-
icance of these syndromes [10,12-15] there is still an
ongoing debate on whether or not these syndromes
require treatment [16].
The bulk of research focusing on associations between
depressive symptoms or disorders and CVD has docu-
mented increased prevalence of depression (ranging from
16% to 23%) among patients with various manifestations
of coronary heart diseases (CHD), including myocardial
infarction (MI), unstable angina, stable coronary artery
disease, congestive heart failure and coronary catheteriza-
tion or angioplasty. The presence of depression in patients
with established CHD was found to be a predictor of poor
course with increased mortality (reviews: [17-19]). Con-
versely, population-based prospective studies on individ-
uals with depression or depressive symptoms have
documented increased cardiovascular morbidity and
mortality in these individuals, thereby implicating depres-
sion as an independent risk factor in the pathophysiologic
progression of CVD, rather than merely a secondary emo-
tional response to the illness [18,20-23]. Other symptoms
and disorders investigated for their association with CVD
were anxiety (review: [24]), heavy drinking (review: [25])
and personality traits [26-33].
However, the existing studies on potential associations
between psychiatric disorders and CVD have suffered
from serious methodological limitations, which are also
likely to account for the large body of conflicting findings.
These methodological limitations include: 1) the use of
clinical rather than epidemiological samples (risk of treat-
ment-seeking bias); 2) the lack of a comparison group; 3)
the application of psychiatric scales for a single psychiatric
syndrome rather than structured diagnostic interviews; 4)
the assessment of the incidence of CVD (or risk factors for
CVD) by interview techniques rather than by physical
examinations, biological measures and the use of medical
records; 5) the lack of assessing both CVD and risk factors
for CVD, which did not allow studies to examine whether
a specific psychiatric disorder was directly associated with
CVD or through associations with already well-estab-
lished risk factors for CVD.
2. Use of population sample for identifying genetic 
variants and biomarkers that can modify the risk for 
psychiatric disorders and could be shared between 
psychiatric disorders and CVD
Association studies represent a very powerful approach for
investigating the biological basis of human diseases, com-
paring genotype frequencies in well-defined clinical
groups to appropriate controls. However, this approach
presents limits: population stratification, genetic hetero-
geneity and phenotype complexity affect the case-control
design of genetic association studies [34]. Moreover, the
real effect of a susceptibility gene and the impact of its dis-
covery in the clinics can only be established using unse-
lected and representative population samples, which
allow for estimating prevalence of gene variants and rela-
tive genotypic disease risks. In recent years, genetics has
greatly advanced and large scale genome-wide association
studies (GWAS) have already delivered numerous new
susceptibility genes for a variety of common conditions
including type 1 and type 2 diabetes, prostate and breast
cancer [35-39]. Other areas are in rapid expansion with
novel loci implicated in the predisposition to complex
traits, such as coronary heart disease, asthma and obesity
[40-42]. The CoLaus study has already contributed to
GWAS successes for several somatic traits including
height, LDL, obesity [42-44] and heavy smoking [45].BMC Psychiatry 2009, 9:9 http://www.biomedcentral.com/1471-244X/9/9
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The clinical practice in psychiatry suffers from the lack of
objective measures. The search of peripheral markers
reflecting psychiatric disease state and trait, and objective
read-outs of response to treatment has been under con-
stant scrutiny for several decades and numerous candi-
dates have been tested based on several disease
pathogenetic hypotheses. Whilst biomarkers are recog-
nized as a great need across all disease areas, the need is
possibly even more important for psychiatric disorders
where disease aetiology is unknown and there is a lack of
objective diagnostic criteria. However, the relevance of
periphery biomarkers for common psychiatric disorders
remains to be demonstrated. Recent developments in pro-
teomic and genomic approaches are expanding the
number of testable hypothesis by some orders of magni-
tude and allowing the exploration of patterns or signa-
tures rather than single markers (see [46] for a review).
Expectations are that, with the decreasing costs of
genomic and proteomic applications, the investigation of
large population-based data sets will provide the opportu-
nity to identify more homogeneous disease subtypes and
investigate biomarkers, so that biomarker studies may
substantiate disease sub-groups. PsyCoLaus represents
therefore a great opportunity to also investigate the pres-
ence of periphery biomarkers related to behavioral traits
[46].
3. Specific aims of the CoLaus/PsyCoLaus study
The PsyCoLaus study is based on the large epidemiologi-
cal sample of the CoLaus survey, which assessed CVD risk
factors and the genetic variants associated with these con-
ditions in the general population of the City of Lausanne
[47]. The specific aims of the PsyCoLaus investigation
were to 1) establish the lifetime and 12-month prevalence
of threshold (DSM-IV) and subthreshold psychiatric syn-
dromes and migraine in 35 to 66 year-old residents of the
city of Lausanne; 2) test the validity of postulated defini-
tions for subthreshold psychiatric disorders, and espe-
cially mood and anxiety syndromes as well as the concept
of atypical depression using comorbidity patterns, risk of
suicidal attempts, health service use, social functioning
(Global Assessment of Function scores, GAF) and family
history as validator variables; 3) determine the association
between the lifetime history of major depressive disorder
(MDD), and other psychiatric disorders and risk factors
for CVD; and 4) identify genetic variants and biomarkers
that can modify the risk for various psychiatric disorders
and for comorbid CVD and psychiatric disorders.
Methods
1. CoLaus and PsyCoLaus
PsyCoLaus is a psychiatric study conducted in a popula-
tion-based cohort assessed for cardiovascular risk factors
(CoLaus) (see [47] for detailed description). In brief, the
CoLaus study, which was based on a sample of 6,738 indi-
viduals randomly selected from the list of residents of the
city of Lausanne (Switzerland), assessed CVD risk factors
and collected DNA and plasma samples for the study of
genetic variants and biomarkers. Lausanne is the 5th larg-
est city of Switzerland, localized in the French speaking
part of the country. Foreigners mostly from other central
European countries represent about a third of the popula-
tion of Lausanne. This proportion is comparable to that of
other Swiss cities, but higher than the average of approxi-
mately 20% in the whole country. Compared to other
European countries, the Swiss population is relatively sta-
ble favoring the completion of prospective follow-up
studies, such as the Zurich cohort study, over decades
[48].
The present study (PsyCoLaus), based on the CoLaus sam-
ple, included a semi-structured diagnostic interview and a
number of self-rating instruments that evaluated person-
ality traits, attitudes, functioning and sleep patterns.
2. Participants
The Institutional Ethic's Committee of the University of
Lausanne approved the CoLaus and subsequently the Psy-
CoLaus study. All participants signed a written informed
consent after having received a detailed description of the
goal and funding of the study.
The recruitment and medical assessment of the CoLaus
sample, which was completed between 2003 and 2006,
has been described in detail [47]. The random sampling
procedure was based on a complete list of the Lausanne
inhabitants aged 35–75 years (n = 56,694 in 2003), pro-
vided by the population register of the city. Of the initial
19,830 subjects sampled, 54 subjects were considered as
non-eligible before contact and 15,109 (76%) responses
were obtained. Among responders, 6,189 (41%) subjects
refused to participate and 799 (5%) were considered as
non-eligible (moved away, out of the age range or
deceased). The sample of 8,121 subjects who agreed to
participate represented 41% of the initially sampled pop-
ulation and 57% of all eligible responders. Among these
subjects, 6,738 completed the examination (6,188 Cauca-
sians and 549 Non-Caucasians), whereas 1,383 could not
be included into the study despite their will to participate
because the number of subjects who agreed to participate
was higher than the number of subjects initially planned
for the CoLaus study (one additional subject withdrew
after consent).
All 35 to 66-year old subjects of the CoLaus sample (n =
5,535), were invited by letters to also participate in the
psychiatric evaluation. Those who did not respond to the
letter were contacted by phone. All subjects who were suf-
ficiently fluent in French or English and agreed to partici-
pate were included into the PsyCoLaus sub-study andBMC Psychiatry 2009, 9:9 http://www.biomedcentral.com/1471-244X/9/9
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underwent the psychiatric assessment between 2004 and
2008.
3. Clinical assessments
Assessment within the CoLaus study [47] included the
collection of socio-demographic, personal and treatment
history data as well as family history information of CVDs
(myocardial infarction, stroke and coronary artery dis-
ease) and their risk factors. In women, further data regard-
ing reproductive and obstetrical history, oral
contraception and hormonal replacement therapy was
collected. The somatic exam encompassed measurements
of body weight, height, blood pressure (triplicate measure
three times on the left arm after at least a 10-minute rest
in the seated position), heart rate (triplicate measure),
waist and hip circumferences, fat and fat-free mass
assessed by electrical bioimpedance [47]. Moreover,
venous blood samples were drawn from each participant
after an overnight fast, in order to measure the levels of
glucose, LDL-cholesterol, HDL cholesterol, and triglycer-
ides. A random subgroup also performed an oral glucose
tolerance test. A urine sample was collected for the assess-
ment of creatinine and albumin. Finally, participants
completed the 12-item General Health Questionnaire
(GHQ-12; [49]; French translation: [50]). This self-rating
instrument was specifically developed to detect the pres-
ence of minor psychiatric symptoms. In a study including
25,916 patients in 15 countries, the GHQ was found to
work as well as the longer 28-item version of the instru-
ment [51]. According to the Likert scoring method, a
threshold score of 12 revealed a sensitivity of 78.9% and
a specificity of 67.4% to detect psychopathology.
Within the PsyCoLaus sub-study, diagnostic information
was collected using the Diagnostic Interview for Genetic
Studies (DIGS, [52]). The DIGS was developed by the
NIMH Molecular Genetics Initiative in order to obtain a
more precise assessment of phenotypes through 1) a semi-
structured design corresponding to a wide spectrum of
DSM-IV Axis I criteria and suicidal behavior, and 2) the
collection of extensive information on the course and
chronology of comorbid conditions. An updated version
of the DIGS [53] includes DSM-IV criteria. The French
translation of the DIGS [54] resulted from a collaborative
effort between the Department of Psychiatry of Lausanne
and the INSERM in Paris. Several modifications were
incorporated into the French version: 1) a screening ques-
tion was added to the mania section to lower the thresh-
old for entering the chapter by asking whether friends or
family members had observed episodes where the sub-
ject's mood was more elated than normal; 2) additional
questions were added to the depression section in order to
elicit criteria for atypical depression features (leaden
paralysis, long-standing patterns of interpersonal rejec-
tion sensitivity, mood reactivity) and recurrent brief
depression (maximal number of episodes within a 12-
month period); 3) a section on generalized anxiety disor-
der (GAD) was added using the questions from the Sched-
ule for Affective Disorders and Schizophrenia – Lifetime
Version (SADS-L, [55]); 4) the brief phobia chapter of the
DIGS was replaced by the corresponding more extensive
chapters from the SADS-L; and 5) the original DIGS sec-
tion on nicotine consumption was largely extended to
elicit DSM-IV abuse and dependence criteria. As long as a
subject was treated in a psychiatric setting in Switzerland,
personal history information was completed by the col-
lection of medical records in order to obtain supplemen-
tary data on symptoms, impairment, duration, timing of
illness and treatment. The applied semi-structured inter-
view allowed for the establishment of lifetime and 12-
month prevalence of a large array of specific DSM-IV axis-
I (threshold) disorders as well as algorithmically-defined
subthreshold mood and anxiety syndromes according to
[8,9]. The French version of the DIGS revealed excellent
inter-rater reliability in terms of kappa and Yule's Y coeffi-
cients for major mood and psychotic disorders [56] and
substance use disorders [57], whereas the 6-week test-
retest reliability was slightly lower [56,57].
Additional data collection based on interview techniques
included headache symptoms ('Diagnostic Interview for
Headache Syndromes' DIHS), life-events (short interview
of F. Amiel-Lebigre; [58]) and family history information.
Family history information was gathered using the modi-
fied version of the Family History-Research Diagnostic
Criteria (FH-RDC; [59], as initially used in the Yale Family
Study [60]. This version (adaptation to DSM-III-R and
DSM-IV) was translated into French by our group, who
undertook extensive validation efforts of this tool by
establishing the agreement and prevalence estimates
between this instrument and semi-structured interviews
for a series of specific psychiatric diagnoses [61,62]. Gen-
erally, the family history method revealed high specificity
but low sensitivity.
Complementary information on personality and temper-
amental features, familial functioning, coping and sleep
were obtained using a self-report battery including the fol-
lowing instruments: the State-Trait Anxiety Inventory
(STAI; [63,64]), the Retrospective Self Report Childhood
Inhibition (RSRCI; [65]), the Dimensions of Tempera-
ment Survey Revised (DOTS-R; [66]), the Eysenck Person-
ality Questionnaire (EPQ; [67,68]), the Type A behavior
[69,70], the Sensitivity to Reward (STR), the Parental
Bonding Instrument (PBI; [71-73]), the Family Adaptabil-
ity and Cohesion Scale III (FACES III; [74,75]), the Dyadic
Adjustment Scale (DAS; [76,77]), the Family Attitude
Scale (FAS-30; [78]), the Euronet: Problem Resolution
Strategy [79] and the MOS-Sleep Module [80].BMC Psychiatry 2009, 9:9 http://www.biomedcentral.com/1471-244X/9/9
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4. Genotyping and biological data
During the CoLaus evaluation, participants donated
blood after a 12-hr fasting period for clinical chemistry
and genetic analyses. Most of the assays were performed
by the Clinical Chemistry Laboratory within the Lausanne
University Hospital. Plasma, serum and RNA are available
for biomarkers studies. Nuclear DNA was extracted from
whole blood for whole genome scan analysis and
genome-wide genotyping was performed on all the 6,188
participants to the CoLaus, using the Affymetrix 500 K
SNP chip. Participants were removed from the analysis on
the basis of the following sample quality control criteria:
any participant whose sex was inconsistent with genetic
data from X-linked SNPs; the proportion of genotypes
called was less than 90%; having inconsistent genotypes
when compared with duplicate samples. In total, 5636
participants remained after sample quality control exclu-
sions. We then applied SNP exclusions with the following
criteria: SNPs that were monomorphic among all samples;
SNPs with genotypes on less than 95% participants; SNPs
that were out of Hardy-Weinberg equilibrium (p < 1·0 ×
10-7). After these quality control procedures, 370 697
SNPs remained for analysis [43].
The inflation factor (λ), which was estimated from the
mean of the χ2 tests generated on all SNPs that were tested,
was calculated to be 1,010. This lambda value, which is
very close to 1, indicates the absence of major population
structure, i.e. that the sample is quite homogeneous genet-
ically [81].
5. Data management and quality control
Interviewers were required to be psychologists or psychia-
trists, who were trained over a two-months period. Their
training included rating tapes and supervised co-ratings.
In order to provide ongoing supervision throughout the
study, each interview and diagnostic assignment was
reviewed by an experienced senior psychologist.
Phenotypic data were entered into a secured, internet-
based database. The database was designed to confirm the
validity of the identification codes, establish the com-
pleteness of the information keyed in and to perform
basic data checks. All discrepancies were recorded in a case
report form kept in a locked room. All modifications of
the data were automatically recorded, including the iden-
tity of the investigator who made each modification, the
date, the old and the new values.
6. Precision of prevalence assessment and power estimates
Within the whole sample, disorders such as schizophrenia
or bipolar-I disorder with an expected lifetime prevalence
of 1% can be estimated with 95% confidence within a
range of +/- 0.31% (i.e. the lower and upper bounds of a
95% confidence interval for a disorder with a 1% preva-
lence would be 0.69% and 1.31%). For more common
disorders, such as MDD, with an expected lifetime preva-
lence of 15%, the prevalence can be estimated within a
range of about +/- 1.1% in the whole sample and within a
range of about +/- 4% in a 5-year age-sex stratum.
The power for the analysis of associations between disor-
ders and dichotomous variables is provided on Table 1
according to the formula for dichotomous variables [82]
and assuming a two-tailed p-value of 0.05. Even for rela-
tively rare disorders or syndromes with a prevalence of 1%
(bipolar disorder or schizophrenia) an association with
correlates present in 25% of the sample (e.g. 25 highest
percentile regarding triglycerides or cholesterol levels)
could be detected with a probability of 63% if the relative
risk is 2 and already 88% if the relative risk is 2.5. How-
ever, typical psychiatric disorders such as MDD docu-
mented to be associated with risk factors for CVD have
prevalence rates of 10% or more. For such conditions, a 2
times increased risk with respect to a correlate present in
5% of the sample (e.g. diabetes) could be detected with a
probability of 97%, whereas a 1.5 times increased risk
could be detected with a probability of 81% for correlates
present in 10% of the sample (e.g. high blood pressure).
For genetic analyses, power calculations were done using
the program Genetic Power Calculator ([83]; http://
pngu.mgh.harvard.edu/~purcell/gpc/).
We have estimated that for a dichotomous trait such as
recurrent MDD – that has a prevalence of around 15% in
the PsyCoLaus cohort – the study has approximately 85%
power to detect an allele with 50% allele frequency that
has a genotypic relative risk = 3 under a dominant model
(type 1 error rate of 10-7 taking into account 500'000
genetics markers). For a continuous behavioral trait such
as Neuroticism that has been measured in our cohort we
would have power of approximately 99% to detect addi-
tive QTL effect that explains 2% of the variance (sample
size = 3000; type 1 error rate of 10-7 taking into account
500'000 genetics markers); power drops rapidly for
smaller effect (i.e. < 2%). However, this large genotypic
relative risk of 3 is unlikely to exist for common traits,
including psychiatric disorders. Therefore, the sample size
in our study does not provide enough statistical power to
detect SNPs with small effects. In order to increase the
power to detect such SNPs, the sample needs to be com-
bined with those of similar studies [84].
Results
1. Recruitment and sociodemographic characteristics of 
the sample
Sixty-seven percent of the participants of the CoLaus study
in the age range between 35 and 66 years accepted the psy-
chiatric evaluation, which resulted in a sample of 3,691BMC Psychiatry 2009, 9:9 http://www.biomedcentral.com/1471-244X/9/9
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individuals who underwent both the medical and psychi-
atric exam. Ninety-two percent of them were Caucasians.
The gender distribution of the PsyCoLaus sample (46.9%
males) did not differ significantly from that of the general
population in the same age range, but the youngest 5-year
band of the cohort was underrepresented and the oldest 5-
year band overrepresented (Table 2). Table 3 provides
socio-demographic characteristics of the sample. The
mean age of the participants was 49.6 years (s.d. 8.8 years)
at the CoLaus and 50.9 (s.d. 8.8 years) years at the psychi-
atric exam. With a representation of 70.7%, Swiss citizens
were over-sampled as their proportion is only 67.8% in
the whole population of the city of Lausanne within the
same age range. Two thirds of the males but only about
half of the females were living with a partner, whereas
more than a quarter of females and a sixth of males were
Table 1: Power for the analysis of the associations between two dichotomous variables (%)
Prevalence of the index disorder Relative risk for the presence of 
the dichotomous correlate in 
individuals with the index disorder
Frequency of dichotomous correlates
1% 3% 5% 10% 15% 25% 50% 75% 90% 95%
1% 1.5 91 2 1 41 82 12 62 81 8 8 5
2 17 25 31 43 52 63 70 52 21 9
2.5 25 39 49 66 77 88 93 83 41 16
3% 1.5 12 19 25 37 46 58 67 51 23 12
2 26 45 59 80 90 97 99 97 70 36
2.5 40 68 83 96 99 100 100 100 96 69
5% 1.5 15 26 35 53 65 79 88 76 41 20
2 34 61 78 94 98 100 100 100 93 64
2.5 53 85 95 100 100 100 100 100 100 94
10% 1.5 21 42 57 81 91 98 100 98 76 46
2 51 87 97 100 100 100 100 100 100 96
2.5 77 99 100 100 100 100 100 100 100 100
15% 1.5 28 57 75 94 99 100 100 100 94 69
2 67 97 100 100 100 100 100 100 100 100
2.5 91 100 100 100 100 100 100 100 100 100
20% 1.5 35 71 88 99 100 100 100 100 99 86
2 80 100 100 100 100 100 100 100 100 100
2.5 98 100 100 100 100 100 100 100 100 100
25% 1.5 42 82 95 100 100 100 100 100 100 95
2 91 100 100 100 100 100 100 100 100 100
2.5 100 100 100 100 100 100 100 100 100 100BMC Psychiatry 2009, 9:9 http://www.biomedcentral.com/1471-244X/9/9
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separated or divorced. The educational level was higher in
males than in females. Similarly, the proportion of profes-
sionally active people was larger in males than females.
The main difference resulted from the fact that 33.2% of
females were housewives, whereas only 2.4% of males
undertook the role of housekeepers. Among the profes-
sionally active persons, the mean degree of professional
activity was 95.4% in males and 74.4% in females.
2. Prevalence of selected cardiovascular risk factors
The prevalence of somatic cardiovascular risk factors such
as obesity (BMI ≥ 30 kg/m2), hypertension (systolic BP ≥
140 or diastolic BP ≥ 90 mmHg or current treatment for
hypertension), diabetes (fasting blood glucose ≥ 7 mmol/
l or current treatment with oral hypoglycemic agents or
insulin) and dyslipidemia (HDL-cholesterol <1.0 mmol/l
or triglycerides ≥ 2,2, mmol/l or LDL cholesterol ≥ 4.1
mmol) was 13.5%, 28.7%, 5.5% and 32.0%, respectively.
Except for diabetes, these rates were slightly lower than
those in the CoLaus sample (14.8%, 31.3%, 5.5%, 33.8%,
respectively), indicating that individuals exhibiting obes-
ity, hypertension and dyslipidemia were slightly less
prone to participate at the psychiatric evaluation than
those without these cardiovascular risk factors.
3. General Health Questionnaire (GHQ) data
Among the 5,230 participants of CoLaus aged between 35
and 66 years 5,020 responded to all questions of the
GHQ-12 (96.0%), which allowed for an estimation of
potential selection bias due to non-participation in Psy-
Table 2: Age and sex distributions of the sample
Age Recruited sample (n = 3691) Difference recruited vs. intended sample according to the distribution in the general population (%)
Males Females All Males Females All
35–39 322 327 649 -19.1 -14.6 -16.9
40–44 337 343 680 -2.8 -3.0 -2.9
45–49 321 333 654 6.2 7.1 6.7
50–54 250 319 569 0.5 11.7 6.5
55–59 217 287 504 -11.8 0.1 -5.4
60–66 283 352 635 22.3 18.2 20.0
35–66 1730 1961 3691 -2.4 2.3 0.0
Sex: χ2 = 1.0; df = 1; p = n.s.
Age: χ2 = 25.4; df = 5; p = < 0.0001
Table 3: Socio-demographic characteristics of the PsyCoLaus sample
Overall (n = 3691) Males (n = 1730) Females (n = 1961)
Race (%)
Caucasians 92.1 92.7 91.6
Age (mean, s.d.)
Somatic exam 49.6 (8.8) 49.2 (8.8) 50.0 (8.8)
Psychiatric exam 50.9 (8.8) 50.5 (8.8) 51.3 (8.8)
Citizenship
Swiss 70.6 66.8 74.0
Marital status (%)
Single 15.6 14.6 16.5
Married/cohabitation 58.6 67.0 51.1
Divorced/separated 22.7 17.3 27.5
Widowed 3.1 1.2 4.8
Education (%)
Basic 16.1 14.0 17.9
Apprenticeship 37.4 37.5 37.4
High school/college 18.6 15.0 21.7
University 28.0 33.6 23.1
Work status (%)
Professional 57.3 75.1 41.6
Unemployed 3.1 3.8 2.4
Retired 9.2 7.7 10.6
Disabled/sick 8.8 9.1 8.4
Other 21.7 4.2 37.0BMC Psychiatry 2009, 9:9 http://www.biomedcentral.com/1471-244X/9/9
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CoLaus. However, GHQ-12 scores between participants
and non-participants of the psychiatric exam did not dif-
fer significantly (z = 1.92; p = n.s.). The mean scores
according to the Likert method were 11.11 (s.d = 4.63)
and 10.87 (s.d. = 4.60), respectively. Moreover, after
adjustment for multiple testing according to Bonferroni,
GHQ-12 scores did not differ according to the presence or
absence of the somatic cardiovascular risk factors obesity,
hypertension, diabetes or dyslipidemia. This lack of asso-
ciation was observed in both the participants and non-
participants of PsyCoLaus.
4. Family history information and additional phenotypic 
data collection
A total of 23,238 family history reports could be collected
from 3,310 subjects (mean: 7 records per subject). These
reports included 6,558 reports on parents, 7,501 on sib-
lings, 517 on half-siblings, 4,984 on children and 3,462
on spouses. Moreover, according to the DIGS interview
892 respondents (24.2%) reported that they suffered from
headache. Consequently, these symptoms were investi-
gated in detail using the DIHS. Finally, 71.6% of the par-
ticipants completed the self report battery.
Discussion
1. Suitability of the study design
The herein presented PsyCoLaus study combines an inves-
tigation of cardiovascular risk factors with a comprehen-
sive psychiatric assessment and the collection of DNA in
individuals recruited from the general population. The
large majority of previous research on associations
between psychiatric disorders and CVD included depres-
sion rating scales rather than diagnostic interviews. Only
four studies (two of them based on the same sample) elic-
ited criteria for depression using structured diagnostic
interviews. However, in these studies most data on
somatic risk factors for CVD were collected using reports
from study subjects (see additional file 1: Table 4), which
entailed the risk of inaccurate information and affected
the ability to accurately adjust for them in the analyses.
Moreover, all these studies focused on depression only
and did not determine the effects of potential comorbid
conditions such as anxiety disorders. In addition, none of
these studies included genotype assessment.
The CoLaus/PsyCoLaus design has attempted to over-
come a series of limitations of previous research that
focused on associations between psychiatric disorders and
risk factors for CVD. Besides the use of a sample recruited
in the general population, which should prevent the risk
of Berkson's bias and minimize the problem of inappro-
priate comparison groups, the application of a semi-struc-
tured psychiatric interview and a thorough somatic
investigation including also blood chemistry measures
ensures the collection of valid data on both psychiatric
disorders and risk factors for CVD. The simultaneous
assessment of a large array of DSM-IV axis-I disorders also
allows for the identification of specific psychiatric disor-
Table 4: Studies of associations between psychiatric disorders and cardiovascular diseases including diagnostic interviews for 
psychiatric disorders
Sample Assessed cardiovascular risk factors
Study authors Target population 
and Age at baseline 
(years)
N (males/
females)
Diagnostic 
interview for 
psychiatric 
disorders
Psychiatric 
disorders 
analyzed
Outcome 
measure
Socio- 
demographic 
variables
Measured 
medical 
variables
Self-reported 
variables
Genetic 
testing
Aromaa et al. 
(1994)
Finnish adults
> 40
3811 
(1825/1986)
Present State 
Examination 
(PSE)
Depression Fatal cardio-
vascular 
disease
Age No
Pratt et al. 
(1996)
US adults 
(ECA study, 
Baltimore)
> 18
1551* 
(583/968)
Diagnostic 
Interview 
Schedule (DIS)
Depression 
Dysphoria
Non-fatal 
myocardial 
infarction
Age Sex 
Marital status
Hyper-tension No
Larson et al. 
(2001)
US adults 
(ECA study, 
Baltimore)
> 18
1703* 
(632/1071)
Diagnostic 
Interview 
Schedule (DIS)
Depression 
Dysthymia
Stroke (fatal 
and non fatal 
measures 
combined)
Age Sex 
Education
Diabetes 
Blood-
pressure 
Heart-
problems 
Smoking
No
Penninx et al. 
(2001)
Dutch older adults 
(LASA study)
55–85
2847 
(1367/1480)
Diagnostic 
Interview 
Schedule (DIS)
Major 
depression 
Minor 
depression
Fatal cardio-
vascular 
disease
Age Sex 
Education
Hyper-tension 
BMI
Diabetes 
Stroke Lung-
disease 
Cancer 
Smoking 
Alcohol
No
Current study Swiss urban adults 
(CoLaus/PsyCoLaus)
35–66
3691 
(1730/1961)
Diagnostic 
Interview for 
Genetic 
Studies (DIGS)
Depression 
Anxiety 
disorders 
Substance use 
disorders
Coronary 
heart- disease, 
stroke
Age Sex 
Education 
Marital status
Hyper-tension 
Diabetes 
Dyslipi-demia 
BMI
Smoking 
Alcohol 
Physical- 
activity
Yes
* = CVD free population at entryBMC Psychiatry 2009, 9:9 http://www.biomedcentral.com/1471-244X/9/9
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ders which are most strongly associated with risk factors
for CVD. In contrast to the bulk of previous population-
based research in psychiatry, the applied semi-structured
interview also enables the assessment of algorithmically-
defined mood and anxiety syndromes below the level of
DSM-IV and of their clinical impact.
There is general consensus among geneticists and genetic
epidemiologists [85-89] on the value of conducting
genetic studies in large population-based association
studies. Susceptibility genes for common diseases are by
and large identified in clinical samples and very often in
narrowly defined categories of disorders in order to
increase power since most severe conditions are associ-
ated with higher genetic loading (e.g. recurrent MDD).
Genetic studies in the community are essential to deter-
mine the genetic risk attributable to susceptible gene vari-
ants at a population level for both narrowly and broadly
defined disorders. They also provide the opportunity to
estimate a population based genotype relative risk. The
PsyCoLaus study offers such a unique opportunity and, in
addition, it provides the chance to identify genetic vari-
ants that may be shared risk factors for psychiatric disor-
ders and CVD.
2. Limitations
Limitations mainly result from constraints regarding the
sample and the cross-sectional design. Indeed, the com-
prehensive physical exam, blood chemistry tests including
fasting glucose and DNA collection is easier to organize in
an urban area with a central hospital, where the clinical
and laboratory research team is localized. However, urban
populations are generally not representative of the whole
country, as they typically include an increased proportion
of diseased subjects. This could be reflected by the mean
GHQ score of the sample, which was higher than in a pop-
ulation-based Australian study [90]. Indeed, as GHQ
scores did not differ between participants of CoLaus who
accepted and those who refused the psychiatric exam,
either the general population of the city of Lausanne
reveals a relatively high level of psychopathology or those
with increased levels of psychopathology were already
more likely to participate in the original CoLaus study.
The over-representation of diseased or disabled subjects in
an urban region would entail the establishment of
increased prevalence estimates as compared to the general
population of a country, whereas the assessment of asso-
ciations between psychiatric disorders and risk factors for
CVD as well as genetic analyses should be at least less
affected or not affected by the choice of the population.
Indeed, there was no evidence for differential associations
between somatic risk factors for CVD and GHQ-scores
according to participation status, although individuals
exhibiting these risk factors were slightly less likely to par-
ticipate at the psychiatric evaluation.
The comprehensive assessment including several distinct
components has certainly contributed to the relatively
low participation rate. Nonetheless, the response rate of
67% for the psychiatric part was very similar to that of the
EPIC-Norfolk United Kingdom Prospective Cohort Study
(response rate = 72%; Surtees et al. 2008), which, how-
ever, was based on a self-assessment approach and did not
include a diagnostic interview. Given the time-consuming
psychiatric evaluation, it is not surprising that 35 to 39-
year-old individuals with typically high levels of profes-
sional activity and familial constraints revealed the lowest
and the 60 to 66 year-old mostly retired individuals the
highest response rate. As specific data on the work/disabil-
ity status for the general population of the city of
Lausanne could not be obtained, it was not possible to
test the presence of selection bias with respect to work/dis-
ability status.
The requirement to be fluent in French or English to com-
plete the psychiatric interview has only slightly reduced
the participation of foreigners. Nevertheless, morbidity
estimates for specific groups of migrants could be biased
in the case of an association between the level of social
integration and morbidity.
Another limitation is the cross-sectional study design,
which does inherently not allow us to easily distinguish
between cause and consequence (temporal ambiguity)
given the risk of inaccurate recall of the onset of diseases.
For this reason, potential associations between psychiatric
disorders and risk factors for CVD will be difficult to inter-
pret regarding the direction of causality.
Finally, the sample size is still too small to detect SNPs
with small effects as expected for psychiatric disorders.
Therefore, in order to increase the power to detect such
SNPs, the sample needs to be combined with those of
similar studies.
3. Perspectives
As the sample of individuals suffering from threshold and
subthreshold mood and anxiety syndromes constitutes an
ideal proband group for an epidemiological family study,
we will also investigate all available first-degree relatives
of the PsyCoLaus sample within the next two years using
the same psychiatric assessments. In the present study,
probands were asked whether they would allow us to con-
tact their first-degree family members and spouses. Such a
population-based family study will allow for the testing of
the generalizability of findings from existing family stud-
ies, which were based on clinical probands, and will
extend the scope from DSM-IV disorders to subthreshold
syndromes.BMC Psychiatry 2009, 9:9 http://www.biomedcentral.com/1471-244X/9/9
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Moreover, a longitudinal follow-up of all participants of
the PsyCoLaus study is planned. More than 95% of the
sample has consented to be contacted for follow-up.
Conclusion
Despite limitations, the presented study should signifi-
cantly contribute to the current scientific knowledge and
subsequent clinical benefice by: 1) establishing the poten-
tial clinical relevance of specific psychiatric syndromes
below the threshold of DSM-IV, which will be crucial to
decide whether and which of the postulated subthreshold
syndromes are a public health issue requiring treatment;
2) completing a genome wide association analysis to
identify DNA markers for risk factors for various psychiat-
ric disorders; and 3) assessing the associations between
risk factors for CVD and a large array of psychiatric disor-
ders and personality traits, which should allow for the
identification of specific psychiatric disorders or personal-
ity traits and genetic variants that are most strongly asso-
ciated with risk factors for CVD. The better understanding
of the interplay between specific psychiatric disorders,
personality traits and risk factors for CVD should ulti-
mately lead to the development of more specific and effec-
tive behavioral interventions in individuals suffering from
psychiatric conditions and to a more successful preven-
tion of CVD.
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